JAZZ

Jazz Pharmaceuticals

October 8, 2026 · pre-market

Rarity

2.06

Peak move

−6.91%

Float cap

$13.5B

Jazz Pharmaceuticals is a global biopharmaceutical company that develops and markets medicines for serious diseases with limited or no therapeutic options. It sells branded therapies to patients and prescribers through two main franchises: neuroscience, chiefly the low-sodium oxybate Xywav for narcolepsy and idiopathic hypersomnia and the cannabidiol drug Epidiolex for severe epilepsies, and oncology, including Zepzelca, Rylaze, Ziihera, Vyxeos and Modeyso.

• analyst_ratingOct 8

  RBC Capital Markets maintained its Buy rating on Jazz Pharmaceuticals plc, per a report dated October 8, 2026.

  Webit.marketscreener.com
• Key eventanalyst_ratingOct 7

  Truist Financial maintained a Buy rating on Jazz Pharmaceuticals and raised its price target to $286.00 from $281.00 on October 7, 2026.

  Webmarketbeat.comWebstockanalysis.com
• Key eventanalyst_ratingOct 7

  RBC Capital lowered its price target on Jazz Pharmaceuticals to $296 from $299 while keeping an Outperform rating, in a research note adjusting models and previewing Q3 biotech results.

  Webtipranks.com
• Key eventinstitutional_flowOct 7

  On October 5, 2026, ETFs bought Jazz Pharmaceuticals shares for net ETF buying of $30.4 million, led by First Trust Health Care AlphaDEX (FXH) with 93,972 shares worth $22.2 million.

  Webgurufocus.comWebgurufocus.com
• insider_saleOct 6 · 16:24 ET

  Jazz Pharmaceuticals President and CEO Renee D. Gala sold 2,000 ordinary shares at $236.40 per share on October 6, 2026 under a Rule 10b5-1 plan adopted June 4, 2026, leaving her 141,394 shares held directly.

  Webrallies.aiWebkalkine.comWebjazzpharma.gcs-web.comWebarchive.fast-edgar.comWebkalkine.comWebdefenseworld.net
• insider_saleOct 5

  Jazz Pharmaceuticals director Bruce Cozadd sold 6,000 shares at $236.40 on October 1, 2026, leaving him 345,875 shares held directly, per an SEC Form 4; he has sold 143,500 shares over the past year.

  Webgurufocus.com